2019
DOI: 10.1016/j.transproceed.2019.04.021
|View full text |Cite
|
Sign up to set email alerts
|

Cutaneous Metastasis as a Presenting Feature of Renal Adenocarcinoma in a Renal Transplant Recipient: A Case Report

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
2
0
2

Year Published

2020
2020
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 9 publications
0
2
0
2
Order By: Relevance
“…[9][10][11] However, some examples with distant metastasis are reported but none of them into the renal allograft. 9,[11][12][13][14][15][16] Also, tumours of other origin than kidney seem to rarely metastasize into the allograft in kidney transplant recipients. We could only find one single report of a metastatic allograft lesion originating from a urothelial carcinoma of the recipient.…”
Section: Discussionmentioning
confidence: 99%
“…[9][10][11] However, some examples with distant metastasis are reported but none of them into the renal allograft. 9,[11][12][13][14][15][16] Also, tumours of other origin than kidney seem to rarely metastasize into the allograft in kidney transplant recipients. We could only find one single report of a metastatic allograft lesion originating from a urothelial carcinoma of the recipient.…”
Section: Discussionmentioning
confidence: 99%
“…The bibliographies of the remaining results were analysed to look for additional relevant cases. In total, there were 25 reported cases of soft tissue metastasis as the first presentation of RCC found 11–22…”
Section: Discussionmentioning
confidence: 99%
“…(20) La decisión terapéutica es individualizada y requiere de manejo multidisciplinario dependiendo el estadio, la extensión y el estado funcional del paciente en cuestión, como podemos observar en la Tabla 1 donde se presenta el manejo de las metástasis cutáneas por cáncer renal en casos reportados de 2015 a 2020 y su evolución posterior. (3,(16)(17)19,(21)(22)(23)(24)(25)(26)(27)(28) Debido a que se trata de una entidad rara, nos encontramos ante pocos datos sobre el manejo óptimo de estos pacientes, encontrándose que en la actualidad no existe un tratamiento estándar o de primera línea para pacientes con sRCC. (29) La diferenciación sarcomatoide presenta pobre respuesta a tratamientos actualmente empleados, como el sunitinib, al compararlo con carcinomas renales sin este tipo de diferenciación incluso en estadios avanzados.…”
Section: Discussionunclassified